News
Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
FEATURED STORIES
As antibody-drug conjugates advance and move into earlier lines of treatment, drug developers have to build gentler therapies that don’t just extend survival but improve it.
FDA’s rare disease decisions are strongest when the patient community has a voice in advisory committee decisions.
The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Two companies reported regulatory submissions to the FDA, and a third reported successful clinical trial data that will form the basis of submission in the coming months.
Cognition Therapeutics, Pyxis Oncology and IsoPlexis Corp. all announced IPO plans.
Acting FDA Commissioner Janet Woodcock’s days as interim head of the agency are numbered due to federal regulations. Speculations are rampant on a number of potential choices.
As US vaccination rates have been hovering in the 50% of the population range for two months, President Biden hit the old dusty trail to push his vaccine mandate even more.
Based on results from the Phase II and Phase III TAK-620-303 (SOLSTICE) trials, members of the AMDAC unanimously voted in favor of using maribavir.
Allogene placed its study on hold after sending a notification to the U.S. FDA about a chromosomal abnormality in its ALPHA2 study patient.
Patients and patient organizations, which have detailed insights in the natural history of a rare disease, should be integral, too.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Intergalactic Therapeutics closed on a Series A funding round worth $75 million. The company was launched by Advanced Technology Products Corporation (ATP).
Workplace issues can arise anytime so it is always better to be prepared to seek out the problems directly in a mannered way to avoid any kind of personal rivalry.